EnSite Derexi
Device
Abbott Laboratories
Total Payments
$2.3M
Transactions
486
Doctors
4
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $2.3M | 486 | 4 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.3M | 482 | 100.0% |
| Food and Beverage | $77.84 | 4 | 0.0% |
Payments by Type
Research
$2.3M
482 transactions
General
$77.84
4 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| TactiFlex PAF IDE | Abbott Laboratories | $915,912 | 0 |
| FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of VT | Abbott Laboratories | $473,461 | 0 |
| Implantation of the HeartMate 3 in Subjects with Heart Failure using Surgical Techniques Other Than Full Median Sternotomy | Abbott Laboratories | $282,790 | 0 |
| TactiFlex IDE | Abbott Laboratories | $277,005 | 0 |
| Safety and Effectiveness of TactiCath Contact Force, Sensor Enabled (TactiCath SE) Catheter for Ablation of Drug Refractory, Symptomatic, Persistent Atrial Fibrillation (PERSIST-END Trial) | Abbott Laboratories | $194,873 | 0 |
| CentriMag Failure-to-Wean Post Approval Study | Abbott Laboratories | $112,176 | 0 |
| Multi-Center Acute Safety Trial of TactiCath Contact Force Ablation Catheter, Sensor Enabled (TactiCath SE) for the Treatment of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation | Abbott Laboratories | $25,961 | 0 |
| LIFE-BTK Randomized Controlled Trial | Abbott Laboratories | $21,540 | 0 |
| TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation Post Approval Study | Abbott Laboratories | $16,865 | 0 |
| Prospective, multicenter, post-market, single-arm, observational study | Abbott Laboratories | $8,810 | 0 |
| A Clinical Evaluation using EnSite Precision Cardiac Mapping System (software version 2.0.1 or higher) in a Real-World Environment | Abbott Laboratories | $5,000 | 0 |
Top Doctors Receiving Payments for EnSite Derexi
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Buffalo, NY | $2.3M | 482 |
| , MD | Clinical Cardiac Electrophysiology | Greenwood, SC | $25.80 | 1 |
| , M.D., M.A | Cardiovascular Disease | Overland Park, KS | $21.67 | 1 |
| Catherine Cheshire | Family | Shawnee, KS | $21.67 | 1 |
| , MD | Cardiovascular Disease | San Juan, PR | $8.70 | 1 |
Ad
Manufacturing Companies
- Abbott Laboratories $2.3M
Product Information
- Type Device
- Total Payments $2.3M
- Total Doctors 4
- Transactions 486
About EnSite Derexi
EnSite Derexi is a device associated with $2.3M in payments to 4 healthcare providers, recorded across 486 transactions in the CMS Open Payments database. The primary manufacturer is Abbott Laboratories.
Payment data is available from 2021 to 2021. In 2021, $2.3M was paid across 486 transactions to 4 doctors.
The most common payment nature for EnSite Derexi is "Unspecified" ($2.3M, 100.0% of total).
EnSite Derexi is associated with 11 research studies, including "TactiFlex PAF IDE" ($915,912).